1808248-05-6
1808248-05-6
Chemical Structure
Linvencorvir
Synonym(s): RG7907; RO7049389
- CAS No.: 1808248-05-6
- Formula:C29H35FN6O5S
- Molecular Weight:598.69
IUPAC Name: 3-((S)-7-(((S)-5-(ethoxycarbonyl)-6-(3-fluoro-2-methylphenyl)-2-(thiazol-2-yl)-1,6-dihydropyrimidin-4-yl)methyl)-3-oxohexahydroimidazo[1,5-a]pyrazin-2(3H)-yl)-2,2-dimethylpropanoic acid
InChIKey: YLJBFYZGSKMBEZ-MBSDFSHPSA-N
SMILES: CCOC(C1=C(CN2C[C@]3([H])N(C(N(C3)CC(C)(C)C(O)=O)=O)CC2)N=C(C4=NC=CS4)N[C@@]1([H])C5=C(C(F)=CC=C5)C)=O
Biological Activity: Linvencorvir (RG7907) is an orally active Hepatitis B virus core protein allosteric modulator. Linvencorvir induces Apoptosis. Linvencorvir has antiviral activity against HBV[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Linvencorvir | 98.14% | Linvencorvir (RG7907) is an orally active Hepatitis B virus core protein allosteric modulator. Linvencorvir induces Apoptosis. Linvencorvir has antiviral activity against HBV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Linvencorvir (Standard) | ≥98% | Bendiocarb (Standard) is the analytical standard of Bendiocarb. This product is intended for research and analytical applications. Linvencorvir (RG7907) is an orally active Hepatitis B virus core protein allosteric modulator. Linvencorvir induces Apoptosis. Linvencorvir has antiviral activity against HBV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Morphothiadin | 99.79% | Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir (HY-B1826)-resistant HBV with an IC50 of 12 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Morphothiadin mesylate | Morphothiadin (GLS4) mesylate is a potent inhibitor of wild-type and Adefovir (HY-B1826)-resistant HBV replication with an IC50 value of 12 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BAY38-7690 | BAY38-7690 is a non-nucleoside inhibitor that inhibits HBV replication. BAY38-7690 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY38-7690 against HBV in stably transfected HepG2.2.15 cells is 0.15 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BAY39-5493 | BAY39-5493 is a non-nucleoside inhibitor that inhibits HBV replication. BAY39-5493 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY39-5493 against HBV in stably transfected HepG2.2.15 cells is 0.03 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HEC72702 | HEC72702 is a potent and orally active hepatitis B virus capsid inhibitor with an EC50 values of 0.039 µM. HEC72702 dose-dependently reduced HBV DNA in both the plasma and livers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RO6889678 | RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HBV-IN-38 | HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC50≤100nM). HBV-IN-38 can be used to study viral infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HBeAg ligand 1 | HBeAg ligand 1 (Compound S2) is a HBeAg inhibitor. HBeAg ligand 1 can be used for synthesis of PROTAC HBeAg degrader-1 (HY-174856). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CAB7-3 | CAB7-3 is an orally active HBV capsid assembly modulator (CAM). CAB7-3 exhibits an exceptional antiviral efficacy reducing HBV DNA with an EC50 = 70 nM, CC50 = 32.3 μM in HepDES19 cells. CAB7-3 exhibits significant anti-HBV activity in HBV-integrated HepDES19 (EC50 = 70 nM), HepAD38 (EC50 = 1 nM) and HBV-infected HLCZ01 cells (EC50 = 2 nM), respectively. CAB7-3 effectively reduces Hepatic HBV core protein levels and suppresses viral replication in vivo. CAB7-3 demonstrates a favorable drug-like and safety profile. CAB7-3 can be used for Hepatitis B Virus (HBV) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-771688 hydrochloride | L-771688 hydrochloride is a potent and highly selective α1A-adrenoceptor antagonist (Kd=43-90 pM). L-771688 hydrochloride is effective against cloned human, rat and dog α1A-adrenergic receptors. L-771688 exhibits high affinity (Ki ≤ 1 nM) and over 500-fold selectivity over the α1B and α1D isoforms. L-771688 potently antagonizes norepinephrine-induced responses at these receptors. Inhibits contractions induced by phenylephrine or A-61603 in rat, dog, human and monkey models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vanrusselt H, et al. Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles. J Virol. 2023 Oct 31;97(10):e0072223. [Content Brief]
- [2]. Zhang Y, et al. Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modelling. Br J Clin Pharmacol. 2023 Oct;89(10):3079-3091. [Content Brief]
- [3]. Zhang W, et al. Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. J Med Chem. 2023 Mar 23;66(6):4253-4270. [Content Brief]
- [4]. Kum DB, et al. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation. Hepatology. 2023 Oct 1;78(4):1252-1265. [Content Brief]
- [5]. Feng S, et al. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01323-20. [Content Brief]
- [6]. Yang L, et al. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infect Dis. 2019 May 10;5(5):713-724. [Content Brief]
